These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34905182)

  • 1. Real-World Treatment Patterns and Health-Resource Utilization in Patients with Hepatocellular Carcinoma (HCC) Following Failure of Sorafenib: A Retrospective Chart Review of 127 Patients in South Korea.
    Novick D; Cho JM; Colman S; Szende A
    Drugs Real World Outcomes; 2022 Jun; 9(2):263-274. PubMed ID: 34905182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns and Health Resource Utilization in Patients With Hepatocellular Carcinoma After Failure of Sorafenib in Real-World Setting in Taiwan.
    Novick D; Rajan N; Wei A; Cheng R; Szende A; Baik R; Colman S
    Value Health Reg Issues; 2022 Jul; 30():76-82. PubMed ID: 35278836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.
    Ren SH; Cui ZL; Lang MR; Li Q; Zhang W; Fang F; Wu Q; Cui YL; Li HK; Chen P; Zhang Y; Song T
    J Gastrointest Oncol; 2022 Jun; 13(3):1266-1277. PubMed ID: 35837206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea.
    Novick D; Lee SY; Koo DH; Szende A; Colman S
    J Drug Assess; 2022; 11(1):12-19. PubMed ID: 35967262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
    Hong YM; Yoon KT; Cho M
    BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
    Hsu PY; Cheng TS; Chuang SC; Chang WT; Liang PC; Hsu CT; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Huang JF; Chuang WL; Huang CF; Yu ML
    Cancer Med; 2022 Jan; 11(1):104-116. PubMed ID: 34786871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
    Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
    Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
    Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
    Aly A; Malangone-Monaco E; Noxon V; Henriques C; Benavente F; Kim A
    Curr Med Res Opin; 2020 Nov; 36(11):1813-1823. PubMed ID: 32969741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Treatment for Advanced Hepatocellular Carcinoma.
    Bouattour M; Mehta N; He AR; Cohen EI; Nault JC
    Liver Cancer; 2019 Oct; 8(5):341-358. PubMed ID: 31768344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
    Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
    Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib.
    Lim DH; Casadei-Gardini A; Lee MA; Lonardi S; Kim JW; Masi G; Chon HJ; Rimini M; Kim I; Cheon J; Hwang JE; Kang JH; Lim HY; Yoo C
    Future Oncol; 2022 Sep; 18(27):3021-3030. PubMed ID: 35903991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
    Finn RS; Yau T; Hsu CH; De Toni EN; Goyal L; Galle PR; Qin S; Rao S; Sun F; Wang C; Widau RC; Zhu AX
    Oncologist; 2022 Dec; 27(12):e938-e948. PubMed ID: 36190331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
    Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
    Tella SH; Kommalapati A; Mahipal A; Jin Z
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure.
    Kuo YH; Yen YH; Chen YY; Kee KM; Hung CH; Lu SN; Hu TH; Chen CH; Wang JH
    Front Oncol; 2021; 11():683341. PubMed ID: 34136408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
    Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
    J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.